Targeted approaches for the management of metastatic prostate cancer

Kathleen W. Beekman*, Maha Hussain

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Huggins and Hodges described the first systemic targeted therapy for prostate cancer in 1941 with their report on the effects of androgen ablation in men with metastatic disease. Since that time, researchers have identified multiple additional "targets" that may be important in prostate cancer tumorigenesis. These areas include continued emphasis on the androgen receptor in the androgen-independent state, parallel growth pathways such as AKT and HER2 that may act in conjunction or independently of the androgen receptor, the supporting environment that allows for the development of metastatic disease, and standard cytotoxic targets, such as the microtubule. This review is intended to highlight these potential targets and several of the agents that are under development in the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)206-212
Number of pages7
JournalCurrent oncology reports
Issue number3
StatePublished - May 2006

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Targeted approaches for the management of metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this